Humacyte, Inc. (NASDAQ:HUMA) is set to release its third-quarter earnings with an anticipated EPS of -$0.17.The company's high price-to-sales ratio of 26.59 indicates strong investor confidence despite modest revenue projections.Financial metrics such as a debt-to-equity ratio of 3.73 and a current ratio of 2.45 highlight both challenges and strengths in Humacyte's financial health.Humacyte, Inc. (NASDAQ:HUMA) is a clinical-stage biotechnology company based in Durham, North Carolina. It focuses on developin ...